Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

Tiacci, Enrico; Park, Jae H.; De Carolis, Luca; Chung, Stephen S; Broccoli, Alessandro; Scott, Sasinya N; Zaja, Francesco; Devlin, Sean M; Pulsoni, Alessandro; Chung, Young R; Cimminiello, Michele; KIM, EUNHEE; Rossi, Davide; Stone, Richard M.; Motta, Giovanna; Saven, Alan; Varettoni, Marzia; Altman, Jessica K.; Anastasia, Antonella; Grever, Michael R.; Ambrosetti, Achille; Rai, Kanti R.; Fraticelli, Vincenzo; Lacouture, Mario E; Carella, Angelo M; Levine, Ross L.; Leoni, Pietro; Rambaldi, Alessandro; Falzetti, Franca; Ascani, Stefano; Capponi, Monia; Martelli, Maria P; Park, Christopher Y.; Pileri, Stefano A.; Rosen, Neal; Foà, Robin; Berger, Michael F.; Zinzani, Pier L.; Abdel-Wahab, Omar; Falini, Brunangelo; Tallman, Martin S.

doi:10.1056/NEJMoa1506583

Record: found
Abstract: found
Article: not found

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

Author(s): Enrico Tiacci, Jae H. Park, Luca De Carolis, Stephen Chung, Alessandro Broccoli, Sasinya N Scott, Francesco Zaja, Sean Devlin, Alessandro Pulsoni, Young Chung, Michele Cimminiello, EUNHEE KIM, Davide Rossi, Richard Stone, Giovanna Motta, Alan Saven, Marzia Varettoni, Jessica Altman, Antonella Anastasia, Michael Grever, Achille Ambrosetti, Kanti R. Rai, Vincenzo Fraticelli, Mario E Lacouture, Angelo Carella, Ross Levine, Pietro Leoni, Alessandro Rambaldi, Franca Falzetti, Stefano Ascani, Monia Capponi, Maria P Martelli, Christopher Y. Park, Stefano Pileri, Neal Rosen, Robin Foà, Michael F. Berger, Pier Zinzani, Omar Abdel-Wahab, Brunangelo Falini, Martin S. Tallman

Publication date: 2015-10-29

Journal: The New England journal of medicine

Read this article at

ScienceOpenPublisher PubMed

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

BRAF V600E is the genetic lesion underlying hairy-cell leukemia. We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues.

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

Read this article at

Abstract

Related collections

Gamma Delta T cells

Author and article information

Journal

Comments

Comment on this article

Similar content 653

Cited by 112